The crosstalk between 5-HT2AR and mGluR2 in schizophrenia

Somdatta Saha, Javier González-Maeso

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


Schizophrenia is a severe brain disorder that usually produces a lifetime of disability. First generation or typical antipsychotics such as haloperidol and second generation or atypical antipsychotics such as clozapine and risperidone remain the current standard for schizophrenia treatment. In some patients with schizophrenia, antipsychotics produce complete remission of positive symptoms, such as hallucinations and delusions. However, antipsychotic drugs are ineffective against cognitive deficits and indeed treated schizophrenia patients have small improvements or even deterioration in several cognitive domains. This underlines the need for novel and more efficient therapeutic targets for schizophrenia treatment. Serotonin and glutamate have been identified as key parts of two neurotransmitter systems involved in fundamental brain processes. Serotonin (or 5-hydroxytryptamine) 5-HT2A receptor (5-HT2AR) and metabotropic glutamate 2 receptor (mGluR2) are G protein-coupled receptors (GPCRs) that interact at epigenetic and functional levels. These two receptors can form GPCR heteromeric complexes through which their pharmacology, function and trafficking becomes affected. Here we review past and current research on the 5-HT2AR-mGluR2 heterocomplex and its potential implication in schizophrenia and antipsychotic drug action.

Original languageEnglish
Article number109489
StatePublished - 1 Jun 2023
Externally publishedYes


  • Antipsychotics
  • Epigenetics
  • G protein-coupled receptor (GPCR)
  • GPCR dimerization
  • Metabotropic glutamate 2 receptor
  • Psychedelics
  • Schizophrenia
  • Serotonin 5-HT receptor


Dive into the research topics of 'The crosstalk between 5-HT2AR and mGluR2 in schizophrenia'. Together they form a unique fingerprint.

Cite this